Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy?

European Respiratory Journal

Volumn 24, Issue 1, 2004, Pages 1-2

  Inman, M ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BIOCHEMICAL MARKER; CORTICOSTEROID; FLUTICASONE; IMMUNOMODULATING AGENT; LAMININ; LEUKOCYTE ANTIBODY;

AIRWAY; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; EDITORIAL; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOMODULATION; NONHUMAN; OUTCOMES RESEARCH; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROVOCATION TEST; SENSITIZATION; TREATMENT PLANNING;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHIAL HYPERREACTIVITY; HUMANS; MICE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 3543118488     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00044304     Document Type: Editorial

References (6)

1. James AL, Pare PD, Hogg JC. The mechanics of airway narrowing in asthma. Am Rev Respir Dis 1989; 139: 242-246.
2. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A, Olivieri D. Airways remodeling is a distinctive feature of asthma and is related to severity of disease. Chest 1997; 111: 852-857.
3. Christie PE, Jonas M, Tsai C-H, Chi EY, Henderson WR Jr. Increase in laminin expression in allergic airway remodelling and decrease by dexamethasone. Eur Respir J 2004; 24: 107-115.
4. Vanacker NJ, Palmans E, Kips JC, Pauwels RA. Fluticasone inhibits but does not reverse allergen-induced structural airway changes. Am J Respir Crit Care Med 2001; 163: 674-679.
5. Henderson WR Jr, Tang LO, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002; 165: 108-116.
6. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-1721.